Lexeo Therapeutics, Inc.

Historical 13F Holders

Symbol
LXEO
CUSIP
52886X107
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 52886X107 since 12/18/2024, largest first.

Filer % of Class Filed
Balyasny Asset Management L.P. 13G/A
10.0% 11/16/2026
Event 9/30/2026
Affinity Asset Advisors, LLC 13G/A
9.8% 11/13/2026
Event 9/30/2026
Suvretta Capital Management, LLC 13G
7.7% 4/13/2026
Event 4/6/2026
Citadel Advisors LLC 13G/A
7.4% 2/17/2026
Event 12/31/2025
Janus Henderson Group Ltd. 13G/A 7.2% 11/16/2026
Event 9/30/2026
RA Capital Management, L.P. 13G
6.9% 10/27/2025
Event 10/20/2025
BlackRock, Inc. 13G 6.7% 1/21/2026
Event 12/31/2025
Mizuho Financial Group, Inc. 13G/A 6.6% 5/13/2025
Event 3/31/2025
Vestal Point Capital, LP 13G/A
6.3% 11/16/2026
Event 9/30/2026
JPMorgan Chase & Co 13G 5.5% 10/13/2026
Event 9/30/2026
Frazier Life Sciences Public Fund, L.P. 13G/A
5.1% 2/13/2026
Event 12/31/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (10)
State Street Corp 13G 4.4% 11/10/2026
Event 9/30/2026
OrbiMed Advisors LLC 13G/A
3.9% 11/16/2026
Event 9/30/2026
Longitude Capital Partners IV, LLC 13G/A
3.8% 11/14/2025
Event 9/30/2025
Eventide Asset Management, LLC 13G/A
3.7% 2/14/2025
Event 12/31/2024
Omega Fund VI, L.P. 13G/A
3.6% 2/14/2025
Event 12/31/2024
Integrated Core Strategies (US) LLC 13G/A
3.2% 11/7/2025
Event 9/30/2025
D1 Capital Partners L.P. 13G/A
2.9% 5/15/2025
Event 3/31/2025
Adage Capital Management, L.P. 13G/A
0.7% 5/12/2025
Event 3/31/2025
Paradigm Biocapital Advisors LP 13G/A
0% 11/16/2026
Event 9/30/2026
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 154 91.7 M $310M
2026 Q2 143 88.2 M $411M
2026 Q1 141 79.9 M $459M
2025 Q4 146 76.5 M $759M
2025 Q3 109 49.3 M $327M
2025 Q2 91 42.2 M $170M
2025 Q1 89 28.0 M $100M
2024 Q4 91 29.5 M $194M
2024 Q3 70 29.7 M $269M
2024 Q2 61 26.6 M $426M
2024 Q1 55 23.1 M $362M
2023 Q4 32 16.2 M $217M